BHC(SH:600721)2022-10-26 16:00Financial Performance - The company's operating revenue for the third quarter was ¥92,595,170.97, representing a year-on-year increase of 43.37%[3] - The net profit attributable to shareholders decreased by 85.82% to ¥701,253.11 compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 97.78% to ¥103,495.14[3] - Basic earnings per share for the third quarter were ¥0.0019, down 85.61% year-on-year[3] - Net profit for the first three quarters of 2022 was ¥10,995,714.37, compared to ¥54,931,343.97 in the same period of 2021, indicating a significant decline[19] - The company reported a basic earnings per share of ¥0.0293 for the first three quarters of 2022, down from ¥0.1463 in the same period of 2021[19] Cash Flow - Cash flow from operating activities increased by 43.63% to ¥11,098,789.78 in the third quarter[3] - The net cash flow from operating activities for the first three quarters of 2022 was ¥20,888,519.77, compared to a negative cash flow of ¥7,698,340.41 in the same period of 2021, indicating a significant improvement[21] - Total cash inflow from operating activities increased to ¥220,602,824.18 in 2022, up from ¥167,389,140.62 in 2021, reflecting a growth of approximately 31.8%[21] - Cash and cash equivalents at the end of the third quarter of 2022 stood at ¥54,839,041.53, up from ¥27,503,292.51 at the end of the same period in 2021, representing a year-over-year increase of approximately 99.5%[22] - The company’s cash flow from operating activities was positively impacted by a tax refund of ¥4,615,176.15 received in 2022, which was not recorded in 2021[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,012,265,016.76, an increase of 3.05% from the end of the previous year[4] - Total liabilities as of September 30, 2022, were ¥307,920,870.93, an increase from ¥296,060,953.02 at the end of 2021[16] - The company's equity attributable to shareholders increased by 3.38% to ¥704,344,145.83 compared to the end of the previous year[4] - The company's equity attributable to shareholders was ¥704,344,145.83 as of September 30, 2022, compared to ¥681,303,920.51 at the end of 2021[16] Expenses - The significant decrease in net profit was primarily due to increased R&D and equity incentive expenses[6] - Sales expenses rose by 107.37% mainly due to the expansion of sales teams at Huawai Medicine and Lihua Biotech[7] - Operating expenses surged by 909.93% mainly due to salary payments for personnel in epidemic-affected areas[7] - Research and development expenses increased to ¥17,282,320.53 in the first three quarters of 2022, up from ¥3,253,778.41 in 2021, reflecting a focus on innovation[18] Investments - Trading financial assets increased by 100% due to the purchase of bank financial products during the period[7] - Investment income plummeted by 190.66% due to increased losses from investments in the associated company Kangyuan Huawai[7] - The company experienced an investment loss of ¥2,283,072.68 in the first three quarters of 2022, compared to a loss of ¥785,486.46 in 2021[18] Shareholder Information - The total number of ordinary shareholders increased from 14,149 to 20,345 during the reporting period[11] - The company acquired a 49% stake in Nanjing Baihua Xinxing Biopharmaceutical Technology Co., Ltd. for 4.9 million RMB, making it a wholly-owned subsidiary[11] - The total share capital increased from 375,134,355 shares to 376,403,355 shares due to stock option exercises[11] Other Income - Other income decreased by 96.77% primarily due to significant debt restructuring gains in the previous year[7]